The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Efficacy of intralesional Rose Bengal in patients receiving injection of all existing melanoma in phase II study PV-10-MM-02.
Sanjiv S. Agarwala
Research Funding - Provectus Pharmaceuticals
John F Thompson
Research Funding - Provectus Pharmaceuticals
B Mark Smithers
Research Funding - Provectus Pharmaceuticals
Merrick I. Ross
Research Funding - Provectus Pharmaceuticals
Charles Raben Scoggins
Research Funding - Provectus Pharmaceuticals
Brendon J Coventry
Research Funding - Provectus Pharmaceuticals
Susan J Neuhaus
Research Funding - Provectus Pharmaceuticals
David R. Minor
Research Funding - Provectus Pharmaceuticals
Jamie M Singer
Employment or Leadership Position - Provectus Pharmaceuticals
Stock Ownership - Provectus Pharmaceuticals
Eric Andrew Wachter
Employment or Leadership Position - Provectus Pharmaceuticals
Stock Ownership - Provectus Pharmaceuticals